RxDoctor Payments Data

Raymond Decker, MD

Family Medicine · Midlothian, VANPI 1972594828

Payments from drug & device makers

$8,497in general payments, 2019–2025

Across 459 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk AS$1K
  • Novo Nordisk$1K
  • AstraZeneca$704
  • Pfizer$690
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$396
  • plus $3K from 47 others

What the payments were for

  • Travel & lodging$1,01712%
  • Food & beverage$7,30586%
  • Education$190%
  • Gifts$471%
  • Other$1101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,497 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$249,170
Medicare patients
529
Services billed
7,851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$93,577
EliquisApixaban60$68,276
JardianceEmpagliflozin24$39,444
XareltoRivaroxaban25$31,834
JanumetSitagliptin Phos/Metformin Hcl20$25,042
Janumet XrSitagliptin Phos/Metformin Hcl12$17,002
TrulicityDulaglutide13$15,051
MounjaroTirzepatide11$10,571
Tresiba Flextouch U-200Insulin Degludec19$7,807
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$7,086
Levothyroxine Sodium418$4,041
Rosuvastatin Calcium338$3,880
Atorvastatin Calcium462$3,799
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl48$3,468
Epinephrine15$3,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,049$93,57776 claims
PfizerEliquis, Paxlovid$690$69,70584 claims
MerckJanumet, Janumet Xr$97$42,04432 claims
Boehringer IngelheimJardiance$67$39,44424 claims
Johnson & JohnsonXarelto$11$31,83425 claims
Lilly USA, LLCTrulicity, Mounjaro$358$25,62224 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$4,041418 claims
AbbVieSynthroid$1,482$1,56161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Midlothian

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →